Syner-G BioPharma Group Acquires RMC Pharmaceutical Solutions
Expands Expertise in Biologics and Builds Scale in CMC and Quality Consulting
BOSTON , Jan. 19, 2023 /PRNewswire-PRWeb/ -- Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of RMC Pharmaceutical Solutions (RMC). Based in Boulder, CO, RMC supports the outsourced CMC and Quality needs of biotech and pharma companies across multiple therapeutic areas.
The acquisition provides additional depth to Syner-G's suite of pharmaceutical science services, adding impressive development experience in all biologic modalities including cell and gene therapy. The combined team offers an impressive range of process and analytical development services, regulatory strategy, regulatory submission support, and quality management services. For RMC, the acquisition provides biotech and pharma clients access to a full range of integrated development and regulatory services.
Syner-G and RMC have strong records of consistent growth and success in providing customized solutions to support the development of life enhancing and lifesaving therapeutics. The combination enhances their ability to deliver the highest caliber CMC services to pharma and biotech companies of all sizes on a global basis.
"I am very pleased to welcome the RMC team to Syner-G," said Ron Kraus, chief executive officer, Syner-G BioPharma Group. "RMC's Biologics experience and their 'Responsive, Measured, and Creative' approach to product development fits perfectly with Syner-G's vision to be the trusted development partner to our clients, recognized globally for our strategic, innovative, and scientifically-driven approach."
Led by founders, Timothy Joy and Scott Rudge, RMC has provided practical and science-driven CMC and Quality solutions to its clients for over 18 years.
"Our clients have come to expect high levels of critical thinking, informed by the best science and engineering, applied reliably, nimbly, and phase appropriately to solve problems and advance their programs," said Scott Rudge, co-founder, chairman, and chief operating officer of RMC. "We know that's exactly what they will continue to receive from Syner-G and I'm delighted to continue to play a key role in the combined business." Timothy Joy, co-founder, president, and chief executive officer of RMC added, "In addition to the obvious benefits the combined organization presents to RMC's clients, I'm excited about the future opportunities that being part of a larger organization offers to the RMC team."
Financial terms of the transaction, which closed in January 2023, were not disclosed.
About Syner-G BioPharma Group
Based in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, visit http://www.synergbiopharma.com.
About RMC Pharmaceutical Solutions
Based in Boulder, CO, RMC specializes in providing CMC and quality management services for the pharmaceutical and biotech sector. For more information, visit http://www.rmcpharma.com.
Media Contact
Stephen Coté, Syner-G BioPharma Group, 1 (508) 460-9700, [email protected]
SOURCE Syner-G BioPharma Group
Share this article